drugset / Trial / NCT07169942
Aleniglipron Phase 2 Body Composition Study
Phase 2
Active not recruiting
71 enrolled
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.
Timeline
- Start
- 2025-08-15
- Primary completion
- 2026-08
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aleniglipron | Small molecule | — | Oral |